United Therapeutics
UTHR
302 hedge funds and large institutions have $3.3B invested in United Therapeutics in 2019 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 86 increasing their positions, 132 reducing their positions, and 50 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
6% more call options, than puts
Call options by funds: $33.1M | Put options by funds: $31.2M
1% more capital invested
Capital invested by funds: $3.27B → $3.3B (+$27.6M)
1.38% less ownership
Funds ownership: 95.71% → 94.33% (-1.4%)
6% less funds holding
Funds holding: 320 → 302 (-18)
35% less repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 132
36% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$62.1M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$37.9M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$19.3M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$18.5M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$47.8M |
| 2 |
Goldman Sachs
New York
|
-$32.7M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$32.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.7M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$22.9M |
UTHR Hedge Fund Activity: Q3 2019 in Review
302 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2019, worth a combined $3.3B — up 0.84% from $3.27B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of UTHR and 32 opened new positions — a net loss of 18 holders — while 132 trimmed existing stakes and 86 added.
The largest buyer was Citadel Advisors, adding an estimated $62.1M. The largest seller was AQR Capital Management, cutting an estimated $47.8M.
- 302 institutional investors held United Therapeutics (UTHR) as of Q3 2019, down from 320 in Q2 2019.
- Funds reported $3.3B of United Therapeutics stock for Q3 2019, up 0.84% quarter-over-quarter.
- 32 funds opened new United Therapeutics positions in Q3 2019 and 50 closed out, a net change of -18 holders.
- The largest United Therapeutics buyer in Q3 2019 was Citadel Advisors, an estimated $62.1M added.
- The largest United Therapeutics seller in Q3 2019 was AQR Capital Management, an estimated $47.8M sold.
Based on aggregated 13F filings for Q3 2019.